Introduction

 This chapter is tailored to support candidates preparing for the PEBC exams by providing a foundational overview of anxiety disorders, one of the most prevalent psychiatric conditions, with a lifetime prevalence estimated to affect 31% of individuals. Anxiety disorders impact women more frequently than men, and the age of onset varies depending on the type of disorder. The chronic nature of anxiety is compounded by considerable functional impairment and associated comorbidities such as depression, substance abuse, hypertension, cardiovascular disease, and gastrointestinal disorders. The social and economic costs of anxiety disorders are also substantial, with consequences like absenteeism and decreased productivity at work and school.

 

Goals of Therapy

The primary objectives in treating anxiety disorders are to:

1.    Reduce or Eliminate Symptoms: Aim to minimize or fully alleviate symptoms of anxiety.

2.    Decrease Disability from Anxiety: Focus on reducing the limitations that anxiety imposes on daily activities and personal functioning.

3.    Achieve Complete Symptom Remission and Recovery: Strive for full remission of symptoms and restoration of normal functioning.

4.    Prevent Relapses: Work to prevent future episodes or recurrences of anxiety symptoms.

 

---

Diagnostic Approach

A comprehensive diagnosis for anxiety disorders involves:

1.    Detailed Patient History: This includes evaluating the nature, duration, and onset of symptoms; assessing the extent of any associated disability; reviewing any coexisting medical or psychiatric conditions; and understanding the patient’s medication history and lifestyle habits (e.g., smoking, alcohol, drug use, caffeine intake).

○     Note: When a mood disorder is also present, it is considered the primary diagnosis, although both conditions should be treated concurrently.

2.    Comprehensive Clinical Evaluation: A thorough clinical assessment helps confirm an accurate diagnosis. Refer to DSM-5-TR criteria and diagnostic tables to support this process.

3.    Use of Validated Clinical Scales: Clinicians can use validated tools to enhance symptom detection and provide objective information for treatment planning. Commonly used scales include:

○     Panic Disorder: Panic Disorder Severity Scale (PDSS)

○     Generalized Anxiety Disorder: Hamilton Anxiety Rating Scale (HAM-A)

○     Social Anxiety Disorder: Liebowitz Social Anxiety Scale (LSAS)

4.    Self-reported questionnaires are also helpful for patient monitoring and may include:

○     General Anxiety: Hospital Anxiety and Depression Scale (HADS)

○     Panic Disorder: Panic and Agoraphobia Scale (PAS)

○     Generalized Anxiety Disorder: Generalized Anxiety Disorder 7-item Scale (GAD-7)

○     Social Anxiety: Liebowitz Social Anxiety Scale (LSAS)

5.    Physical Examination: Conduct a physical exam to identify any underlying endocrine or cardiac issues and to detect signs of substance use that may contribute to anxiety symptoms.

6.    Laboratory Testing: Routine lab tests are generally unnecessary but consider thyroid function tests if an underlying endocrine disorder is suspected.

 

DSM-5-TR Anxiety Disorder Classifications and Features

1.    Separation Anxiety Disorder: Excessive fear of separation from key figures (e.g., parents) inappropriate for the developmental stage, typically beginning in childhood.

2.    Selective Mutism: Childhood onset of inability to speak in specific social contexts (e.g., school) despite speaking in other settings, which may hinder academic performance.

3.    Specific Phobia: Intense fear related to particular objects or situations (e.g., spiders, flying) that often results in avoidance.

4.    Social Anxiety Disorder (Social Phobia): Severe anxiety in social or performance situations where one may feel embarrassed, commonly leading to avoidance.

5.    Panic Disorder: Repeated, unexpected panic attacks, accompanied by ongoing fear of recurrence.

6.    Agoraphobia: Significant fear or anxiety about at least two specific situations (e.g., public transportation, crowds), leading to avoidance.

7.    Generalized Anxiety Disorder: Persistent, excessive worry about various aspects of life, occurring most days for at least six months.

8.    Anxiety Due to Another Medical Condition: Anxiety symptoms directly resulting from a medical issue, such as thyroid problems or heart conditions.

9.    Substance/Medication-Induced Anxiety Disorder: Anxiety symptoms triggered by the use or withdrawal of substances like caffeine, alcohol, or certain drugs.

10.  Other Specified Anxiety Disorder: Anxiety symptoms that do not meet full diagnostic criteria for a specific disorder, such as infrequent panic attacks.

 

 Treatment Options

1. Non-Pharmacologic Choices

●     Psychotherapy

○     Cognitive Behavioral Therapy (CBT): CBT is widely used and tailored to specific anxiety disorders, focusing on identifying and changing thought patterns and behaviors that contribute to anxiety. It is effective for various anxiety types, including generalized anxiety disorder and panic disorder.

○     Exposure Therapy: Often part of CBT, this method gradually exposes patients to anxiety-inducing situations, helping reduce the associated fear.

○     Mindfulness-Based Therapy: Incorporates mindfulness techniques to help patients focus on the present moment and reduce anxiety-related stress.

○     Access Alternatives: In areas with limited access to in-person CBT, Internet-Delivered CBT (ICBT) offers a viable option. Studies show that ICBT can improve anxiety symptoms significantly, with no notable difference in effectiveness compared to traditional face-to-face therapy. For example, an ICBT program with weekly therapist support can help patients improve without needing in-person sessions.

●     Lifestyle and Stress Management

○     Stress Reduction: Techniques like relaxation exercises and time management can be useful initial steps in reducing anxiety.

○     Exercise: Aerobic exercise, such as running or swimming multiple times weekly, can alleviate anxiety symptoms, though CBT remains the more effective intervention.

○     Reducing Stimulants and Alcohol: Caffeine and other stimulants should be minimized as they can exacerbate anxiety. Alcohol should also be used minimally, as it can worsen sleep quality and may increase anxiety after long-term use.

○     Drug Use Considerations: Recreational drugs (e.g., cannabis, cocaine) can trigger anxiety and should be avoided. Refer patients to addiction centers if substance use contributes to their anxiety.

●     Sleep and Lifestyle Education

○     Emphasizing balanced lifestyle practices and good sleep hygiene can help manage anxiety symptoms.

2. Pharmacologic Choices

●     Antidepressants

○     SSRIs and SNRIs: Selective serotonin reuptake inhibitors (SSRIs) like sertraline and escitalopram, and serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine, are commonly used as first-line treatments due to their effectiveness and tolerability. They work by increasing serotonin levels in the brain, which helps regulate mood.

○     Dosage and Duration: Start at a low dose, increasing gradually. Optimal effects may take 8–12 weeks or more, so patients should be informed that benefits are gradual and that early side effects (e.g., nausea, headaches) often resolve.

○     Duration of Use: Most patients continue treatment for 12–24 months to achieve full remission and prevent relapse. When discontinuing, taper doses over several months to prevent withdrawal symptoms and anxiety relapse.

●     Benzodiazepines

○     These include lorazepam and clonazepam, which are effective for immediate anxiety relief and can be used short-term at the beginning of treatment. However, due to risks of dependence and cognitive impairment, benzodiazepines are usually a second-line option.

○     Special Considerations: In elderly patients, benzodiazepines should be used cautiously due to risks of falls and cognitive side effects. They are not recommended for individuals with a history of substance use disorder.

●     Other Medications

○     Pregabalin and Gabapentin: Although used for anxiety, these are more suitable for short-term use due to misuse potential, especially in those with a history of substance use.

○     Buspirone: Effective in some anxiety disorders, particularly for generalized anxiety disorder, without the sedative effects of benzodiazepines.

○     Mirtazapine and Trazodone: Sometimes used as adjuncts for anxiety, though they have limited supporting evidence.

●     Antipsychotics and Anticonvulsants: Second- or third-line agents, such as quetiapine, may be considered in treatment-resistant cases or as adjuncts to primary treatment, though side effects limit their use.

3. Combining Psychotherapy and Pharmacotherapy

●     The combination of psychotherapy and pharmacotherapy varies in effectiveness depending on the specific anxiety disorder:

○     Panic Disorder: Combined therapy (e.g., CBT with SSRI like sertraline) has shown enhanced effectiveness.

○     Generalized Anxiety Disorder: Studies do not generally support combining therapy initially.

○     Social Anxiety Disorder: The benefits of combining treatments remain inconclusive; further studies are required.

4. Considerations for Special Populations

●     Youth (Under 18): Antidepressants should be prescribed cautiously due to a potential risk of suicidal ideation in younger patients. Close monitoring is essential.

●     Adults: Although this risk is not typically present in adults, monitoring for any signs of suicidal thoughts is recommended.

 

Understanding Panic Disorder and Agoraphobia

●     Panic Disorder: Characterized by sudden, intense panic attacks that include symptoms such as heart palpitations, trembling, shortness of breath, chest pain, and nausea. At least one panic attack is typically followed by a month or more of worry about future attacks or changes in behavior to avoid triggers.

●     Agoraphobia: In some cases, panic disorder is accompanied by agoraphobia, the fear of places or situations where escape might be difficult, leading individuals to avoid certain locations or situations.

Pharmacological Treatments for Panic Disorder

First-Line Treatments: SSRIs and SNRIs

●     Selective Serotonin Reuptake Inhibitors (SSRIs): Medications like citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline are commonly prescribed. These drugs work by increasing serotonin levels in the brain, which helps regulate mood and anxiety.

●     Serotonin-Norepinephrine Reuptake Inhibitor (SNRI): Venlafaxine is also effective and has shown a response rate of around 75%, similar to SSRIs.

Dosing Consideration: Start with a low dose, as patients with panic disorder may be more sensitive to side effects. Gradually increase the dose to minimize initial side effects like anxiety or agitation, which may discourage adherence.

Second-Line Treatments: TCAs and Benzodiazepines

●     Tricyclic Antidepressants (TCAs): Imipramine and clomipramine are effective but are considered second-line because they have more side effects, including the potential for toxicity in overdose situations.

●     Benzodiazepines: Alprazolam, clonazepam, lorazepam, and diazepam can provide rapid relief from acute anxiety. However, due to the risk of dependence, abuse, and withdrawal symptoms, they are used primarily in the short term or to manage anxiety at the beginning of antidepressant treatment.

○     Preferred Choices: Clonazepam and lorazepam are generally preferred due to their lower abuse potential. Alprazolam, while fast-acting, has a higher risk of withdrawal symptoms due to its short half-life.

Third-Line Treatments: MAOIs and Other TCAs

●     Monoamine Oxidase Inhibitor (MAOI): Phenelzine may be effective but is rarely used due to its side effects, dietary restrictions, and potential for drug interactions.

●     Desipramine: Although effective in some cases, it is less studied for panic disorder and thus is a third-line choice.

Medications Not Recommended

●     Mirtazapine and moclobemide lack strong evidence for panic disorder.

●     Buspirone, trazodone, and propranolol have not shown effectiveness for this condition.

3. Combined Use of Antidepressants and Benzodiazepines

●     Benzodiazepine-Augmented Therapy: A benzodiazepine may be used together with an SSRI or SNRI during the initial weeks of treatment. This combination can help alleviate anxiety and agitation until the antidepressant reaches full effect, typically after several weeks.

4. Considerations in Treatment Initiation

●     Dosing Strategy: Begin with the lowest possible dose of antidepressants for patients with panic disorder to reduce the risk of heightened anxiety or agitation. Patients should be informed that initial side effects may lessen over time, while therapeutic benefits will increase with continued treatment.

 

 Table 1

 

 

---

1. Understanding Social Anxiety Disorder

●     Definition: Social anxiety disorder, or social phobia, is a common anxiety disorder marked by a fear of criticism or negative evaluation, leading to social avoidance or discomfort with authority figures.

●      

2. Pharmacologic Treatments for Social Anxiety Disorder

First-Line Treatments: SSRIs and SNRIs

●     SSRIs (Selective Serotonin Reuptake Inhibitors): Medications like escitalopram, fluvoxamine, paroxetine, and sertraline have shown effectiveness by increasing serotonin in the brain, which helps reduce anxiety.

●     SNRI (Serotonin-Norepinephrine Reuptake Inhibitor): Venlafaxine is also effective, particularly for social anxiety related to performance situations.

Considerations: These medications are generally well-tolerated and effective for both generalized social anxiety and specific performance-related anxiety.

Second-Line Treatments

●     Pregabalin: This medication is effective at high doses (≥600 mg/day), though lower doses (150–300 mg/day) are less effective. It is a second-line option due to the higher risk of side effects like cognitive impairment and the limited comparative data against SSRIs/SNRIs.

●     Benzodiazepines: Clonazepam and bromazepam can help manage social anxiety but carry risks of dependence, sedation, and withdrawal. They are typically used short-term or in combination with an antidepressant during the initial treatment period.

●     Other Second-Line Options:

○     Phenelzine (MAOI) and Moclobemide: Both have shown some efficacy in studies. However, phenelzine has dietary restrictions, making it less convenient.

○     Citalopram, Mirtazapine, Gabapentin: Limited evidence supports their effectiveness, often from single studies.

Third-Line Treatments

●     Ketamine: Although promising in early studies, ketamine is currently limited in availability, restricting its use as a mainstream treatment for social anxiety.

Note on Performance Anxiety: For specific events like public speaking, propranolol or atenolol can be taken 30–60 minutes before to reduce physical symptoms like rapid heartbeat. However, these medications are not effective for generalized social anxiety.

3. Ineffective Treatments for Social Anxiety Disorder

●     Buspirone and Desvenlafaxine: These medications have been shown to lack effectiveness in treating social anxiety disorder and are generally not recommended.

Table 2: Social Anxiety Disorder

 

 

 

 

 

 

 

 

 

 

 

●     Definition: Characterized by an intense fear of specific objects or situations, like animals, natural disasters, enclosed spaces, or medical procedures (e.g., injections). This fear can lead to avoidance behavior.

Preferred Treatment

●     Exposure Therapy: The most effective treatment for specific phobia, where gradual exposure to the feared object or situation helps reduce anxiety over time.

●     Occasional Pharmacotherapy: Although rarely necessary, medications like alprazolam (a benzodiazepine) or pregabalin can be taken occasionally before facing a feared situation. Fluoxetine (an SSRI) has also shown effectiveness in limited studies for specific phobias.

 

●     Definition: Characterized by excessive, uncontrollable worry about everyday life concerns (e.g., health, finances, family) lasting at least 6 months.

●     Prevalence: Affects around 6% of people over a lifetime, with a higher rate in those over 65 and in women.

●     Comorbidities: GAD often co-occurs with other psychiatric conditions (e.g., depression) and physical disorders (e.g., hypertension, gastrointestinal issues).

First-Line Treatments

●     SSRIs: Escitalopram, paroxetine, and sertraline are effective, working by boosting serotonin to stabilize mood.

●     SNRIs: Venlafaxine and duloxetine are also effective, increasing both serotonin and norepinephrine.

Second-Line Treatments

●     Vilazodone: Shows effectiveness but lacks long-term studies or comparisons with other treatments.

●     Pregabalin: Useful for GAD but has a risk of abuse, making it a second-line option.

●     Benzodiazepines: Medications such as alprazolam, bromazepam, diazepam, and clonazepam can help relieve symptoms but are used cautiously due to risks of dependence and sedation.

●     Imipramine: An effective tricyclic antidepressant for GAD but is limited by its side effects and overdose risk.

Third-Line Treatments

●     Quetiapine: Effective at 50–150 mg daily, but often a third-line option due to side effects like sedation and potential weight gain.

●     Hydroxyzine: Shown to be as effective as benzodiazepines but is limited by side effects.

●     Trazodone and Valproate: Limited evidence of efficacy in GAD.

Refractory GAD (for treatment-resistant cases)

●     Combination Therapy: Olanzapine (an antipsychotic) or pregabalin can be combined with an antidepressant, especially in difficult-to-treat cases.

 

Table 3: Generalized Anxiety Disorder (GAD)

 

 

 

 

 

●     Prevalence: Anxiety affects about 15–20% of pregnant patients, with fluctuations in severity.

●     Impacts: Anxiety disorders during pregnancy can negatively impact both mother and child, sometimes leading to preterm birth or low birth weight. They can also increase the likelihood of depressive symptoms, substance abuse, and preference for cesarean delivery.

Non-Pharmacologic Treatments

●     CBT and Interpersonal Therapy (IPT): These are preferred for mild to moderate anxiety as they are safe and effective. Meditative or relaxation-based therapies are also beneficial and may be more acceptable to pregnant patients.

Pharmacologic Treatments

●     SSRIs (Selective Serotonin Reuptake Inhibitors): Often used for severe anxiety, SSRIs can sometimes cause adverse effects, especially in the first trimester (e.g., spontaneous abortions). Paroxetine is usually avoided due to its link with congenital cardiac abnormalities, while citalopram, escitalopram, and sertraline are preferred.

●     SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors): Limited data suggest they don’t increase major birth defects, but they may pose risks in the third trimester, such as newborn behavioral syndrome.

●     Benzodiazepines: Generally avoided in the first trimester due to potential risks (e.g., low birth weight, preterm birth) and only used if absolutely necessary, under close monitoring.

 

 

 

●     Non-Pharmacologic Approaches: Non-drug methods should be prioritized, especially for breastfeeding mothers.

●     Pharmacologic Treatments: Paroxetine and sertraline are recommended as they have low transfer into breast milk, posing minimal risk to the infant. Benzodiazepines are generally avoided due to risks like sedation in the infant.

 

 

●     Implications: Untreated anxiety can impair social and academic development, potentially leading to adult conditions like depression or substance abuse.

Non-Pharmacologic Treatments

●     CBT: Considered the first-line treatment for children (6–18 years) with mild to moderate anxiety.

Pharmacologic Treatments

●     SSRIs: Effective for more severe cases or when CBT alone is insufficient. Fluoxetine, fluvoxamine, paroxetine, and sertraline have shown benefits but carry a risk of suicidal thoughts, particularly in those under 18.

●     SNRIs: Duloxetine is FDA-approved for GAD in children (7–17 years). Venlafaxine may carry a higher risk of suicide and is used with caution.

 

 

 

 

 

Step 1: Diagnosis of Primary Anxiety Disorder

 

Step 2: Begin Non-Pharmacologic Approach

●     Interventions:

○     Stress Management Strategies: Teach relaxation techniques, time management skills, and recommend aerobic exercise.

○     Lifestyle Modifications: Advise reduction in caffeine and alcohol consumption.

 

Step 3: Consider Short-Term Benzodiazepine Use (If Needed)

●     Objective: Provide rapid relief for severe symptoms if non-pharmacologic approaches are insufficient.

○     Medication Examples: Alprazolam, clonazepam, lorazepam.

●     Timing: Begin for a maximum duration of 2–4 weeks.

 

Step 4: Monitor Non-Pharmacologic Progress

●     Objective: Assess relief from non-pharmacologic interventions.

●     Decision Point:

○     Relief Achieved: Continue non-pharmacologic approach; taper off benzodiazepines if used.

○     No Relief: Proceed to trial of psychotherapy or pharmacotherapy.

 

Step 5: Decide on Psychotherapy or Pharmacotherapy

●     Objective: Choose between psychotherapy and pharmacotherapy based on patient preference and availability of resources.

 

Step 6A: Psychotherapy Pathway (If Chosen)

1.    Minimal Intervention:

○     Therapies: Provide problem-solving support, relaxation techniques, mindfulness, and exposure instructions.

○     Timing: Start at 4–6 weeks, continue for 6–8 weeks.

○     Reevaluation: Check for symptom relief after 6–8 weeks.

■     Relief Achieved: Continue treatment and monitor.

■     No Relief: Refer to a specialized center for intensive Cognitive Behavioral Therapy (CBT).

2.    Intensive CBT:

○     Timing: Begin within 8–12 weeks if minimal intervention is ineffective.

○     Reevaluation: Check for relief after 12–16 weeks.

■     Relief Achieved: Continue monitoring.

 

Step 6B: Pharmacotherapy Pathway (If Chosen)

1.    Initiate SSRI or SNRI Trial:

○     Medications: Start with an SSRI (e.g., escitalopram, sertraline) or SNRI (e.g., venlafaxine).

○     Timing: Begin at 4–6 weeks, with a 6–8 week trial period.

○     Reevaluation:

■     Relief Achieved: Continue treatment and monitor for 1–2 years.

■     Partial Relief: Increase dose and monitor for additional 4–6 weeks.

■     No Relief: Switch to another SSRI or SNRI.

2.    If Partial Relief After Increasing Dose:

○     Objective: Consider additional therapeutic support.

○     Options:

■     Add Adjuvant Therapy: Second-generation antipsychotic or anticonvulsant.

■     Referral: Refer to specialist or center for specialized CBT.

○     Timing: Reassess after 12–16 weeks from initial SSRI/SNRI trial.

3.    If No Relief After Medication Switch:

○     Objective: Try an agent from a different class (e.g., switch from SSRI to SNRI).

○     Referral: Consider referral to a specialist or center for specialized CBT.

○     Timing: Reevaluate after 16–20 weeks from initial SSRI/SNRI trial.